ReviewDrugs2019
Fexinidazole: First Global Approval.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 1 synthesis or guideline pooled it, 205 citations in OpenAlex.
- The anti-Trypanosoma activities of medicinal plants: A systematic review of the literature.Veterinary medicine and science · 2022Pooled it
- Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.PLoS neglected tropical diseases · 2021Trial
- Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo.PLoS neglected tropical diseases · 2020Trial
- Article
- 5‑Nitrofuran-Semicarbazone Hybrids as Antitrypanosomal Agents: Structure-Activity Relationship and Nitroreductase Activation.ACS medicinal chemistry letters · 2026Article
- Nitroquinolones and nitroquinolines: syntheses and antitrypanosomal activity.Molecular diversity · 2026Article
- Synthesis of New Asymmetrical Chalcones and Evaluation of Their Use in Combination with Curcumin Against Rhodesain ofInternational journal of molecular sciences · 2026Article
- Simultaneous Determination of Fexinidazole and Its Major Metabolites in Rat Plasma by UPLC-MS/MS: Method Validation and Application to Pharmacokinetic Study.Drug design, development and therapy · 2026Article
- A CRISPR-based diagnostic tool to survey drug resistance in human African trypanosomiasis.Antimicrobial agents and chemotherapy · 2025Article
- Article
- Optimization of Physicochemical Properties and ADME for 2,4-Substituted 1Journal of medicinal chemistry · 2025Article
- Fexinidazole results in specific effects on DNA synthesis and DNA damage in the African trypanosome.PLoS neglected tropical diseases · 2025Article
- Sustainable Antiparasitic Agents from an Agro-Industrial Waste: Mitochondria-Targeting Cashew Nutshell Liquid-Derived Phosphonium and Ammonium Salts.Journal of medicinal chemistry · 2025Article
- Human African Trypanosomiasis (HAT): Epidemiology, Biological Diagnosis and Treatment: A Review.Acta parasitologica · 2025Review
- Fexinidazole and Corallopyronin A target Wolbachia-infected sheath cells present in filarial nematodes.PLoS pathogens · 2025Article
- Molecular docking to homology models of human and Trypanosoma brucei ERK8 that identified ortholog-specific inhibitors.PLoS neglected tropical diseases · 2025Article
- Crystallographic and Electroanalytical Analyses of Fexinidazole and Its Major Metabolites.ACS omega · 2025Article
- Discovery of Novel CRK12 Inhibitors for the Treatment of Human African Trypanosomiasis: An Integrated Computational and Experimental Approach.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Cytological profiling of trypanocidal principles fromPhytomedicine plus : international journal of phytotherapy and phytopharmacology · 2025Article
- Fexinidazole and Corallopyronin A targetbioRxiv : the preprint server for biology · 2025Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fexinidazole Winthrop (hereafter referred to as fexinidazole) is a DNA synthesis inhibitor developed by the Drugs for Neglected Diseases initiative (DNDi), in collaboration with Sanofi, for the oral treatment of human African trypanosomiasis (HAT) [commonly known as 'sleeping sickness'] and Chagas' disease. The drug is a 5-nitroimidazole derivative first discovered by Hoechst AG (now part of Sanofi) and was identified by the DNDi in 2005 as having activity against Trypanosoma brucei gambiense and T. b. rhodesiense. Under Article 58 of Regulation (EC) no. 726/2004 (a regulatory mechanism for reviewing new medicines destined for use outside of the EU), fexinidazole has been granted a positive opinion by the EMA for the treatment of both the first-stage (haemo-lymphatic) and second-stage (meningo-encephalitic) of HAT due to T. b. gambiense (g-HAT) in adults and children aged ≥ 6 years and weighing ≥ 20 kg. This approval will facilitate and support marketing authorization application in endemic countries in 2019; following registration, fexinidazole will be distributed via the WHO to endemic countries for g-HAT. Phase 3 evaluation of fexinidazole for g-HAT is ongoing in the Democratic Republic of the Congo and Guinea and the drug is also in development for Chagas' disease, with a study currently ongoing in Spain. Clinical development for visceral leishmaniasis is discontinued. This article summarizes the milestones in the development of fexinidazole leading to this first approval for g-HAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.